Estrogen-mediated gut microbiome alterations influence sexual dimorphism in metabolic syndrome in mice

Show simple item record Kaliannan, Kanakaraju Robertson, Ruairi C. Murphy, Kiera Stanton, Catherine Kang, Chao Wang, Bin Hao, Lei Bhan, Atul K. Kang, Jing X. 2019-07-18T12:09:11Z 2019-07-18T12:09:11Z 2018-11-13
dc.identifier.citation Kaliannan, K., Robertson, R.C., Murphy, K., Stanton, C., Kang, C., Wang, B., Hao, L., Bhan, A.K. and Kang, J.X., 2018. Estrogen-mediated gut microbiome alterations influence sexual dimorphism in metabolic syndrome in mice. Microbiome, 6(1): 205. DOI:10.1186/s40168-018-0587-0 en
dc.identifier.volume 6 en
dc.identifier.issued 1 en
dc.identifier.startpage 1 en
dc.identifier.endpage 22 en
dc.identifier.doi 10.1186/s40168-018-0587-0 en
dc.description.abstract Background: Understanding the mechanism of the sexual dimorphism in susceptibility to obesity and metabolic syndrome (MS) is important for the development of effective interventions for MS. Results: Here we show that gut microbiome mediates the preventive effect of estrogen (17β-estradiol) on metabolic endotoxemia (ME) and low-grade chronic inflammation (LGCI), the underlying causes of MS and chronic diseases. The characteristic profiles of gut microbiome observed in female and 17β-estradiol-treated male and ovariectomized mice, such as decreased Proteobacteria and lipopolysaccharide biosynthesis, were associated with a lower susceptibility to ME, LGCI, and MS in these animals. Interestingly, fecal microbiota-transplant from male mice transferred the MS phenotype to female mice, while antibiotic treatment eliminated the sexual dimorphism in MS, suggesting a causative role of the gut microbiome in this condition. Moreover, estrogenic compounds such as isoflavones exerted microbiome-modulating effects similar to those of 17β-estradiol and reversed symptoms of MS in the male mice. Finally, both expression and activity of intestinal alkaline phosphatase (IAP), a gut microbiota-modifying non-classical anti-microbial peptide, were upregulated by 17β-estradiol and isoflavones, whereas inhibition of IAP induced ME and LGCI in female mice, indicating a critical role of IAP in mediating the effects of estrogen on these parameters. Conclusions: In summary, we have identified a previously uncharacterized microbiome-based mechanism that sheds light upon sexual dimorphism in the incidence of MS and that suggests novel therapeutic targets and strategies for the management of obesity and MS in males and postmenopausal women. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Springer Nature en
dc.rights © 2018 The Author(s) en
dc.rights.uri en
dc.subject Estrogen en
dc.subject Gut microbiome en
dc.subject Obesity en
dc.subject Metabolic syndrome en
dc.subject Isoflavones en
dc.subject Chronic inflammation en
dc.title Estrogen-mediated gut microbiome alterations influence sexual dimorphism in metabolic syndrome in mice en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Catherine Stanton, APC Microbiome Ireland, University College Cork, Cork, Ireland. +353-21-490-3000 Email: en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder Sansun Life Sciences en
dc.contributor.funder Fortune Education Foundation en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Microbiome en
dc.internal.IRISemailaddress en
dc.identifier.articleid 205 en
dc.identifier.eissn 2049-2618

Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2018 The Author(s) Except where otherwise noted, this item's license is described as © 2018 The Author(s)
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement